The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
Basic Licensing Agreement Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811
|March 31, 2006|
Japan, March 31, 2006 - Toyama Chemical Co., Ltd. (“Toyama”; headquarters: Tokyo; president and CEO: Katsuhiko Nakano) and Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that they have concluded a basic licensing agreement for the marketing and joint development in Japan of oral formulations of the new-type quinolone antibiotic T-3811 (generic name: garenoxacin) discovered by Toyama. This licensing agreement is based on the letter of intent signed on January 26, 2006.
Profile of T-3811
Development status of T-3811
Toyama and Taisho have agreed that Taisho Toyama markets T-3811 in Japan. Based on the basic licensing agreement signed between Toyama and Astellas, Toyama, Astellas, Taisho and Taisho Toyama will cooperate to maximize the product value of T-3811 in Japan.